Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs Smith & Nephew plc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.49, while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Smith & Nephew plc pays a 2.85% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SGOV | SNN | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $100.72 | $38.53 |
52-Week Low | $100.28 | $27.80 |
Market Cap | — | $11.63B |
Enterprise Value | — | $14.66B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV trades at $100.475 with minimal daily movement, showing price stability amid bearish technical signals. The ETF maintains consistent dividend distributions with recent payouts of $0.30-$0.31 per share. Technical indicators show strong bearish momentum with 17 sell signals versus 3 buy signals, though RSI levels suggest potential oversold conditions. Market sentiment reflects broader Treasury market concerns as rising oil prices fuel inflation worries.
The outlook remains cautious given the bearish technical picture and macroeconomic headwinds from rising Treasury yields. Investors seeking Treasury exposure may find value in SGOV's stability and dividend consistency, though the current environment of rising rates and inflation pressures presents near-term challenges for fixed income ETFs.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
